Evidence map›Paper›PMID 28750664›Full record

Trial reportStem cell research & therapy2017

Harvesting multipotent progenitor cells from a small sample of tonsillar biopsy for clinical applications.

Raju Khatri, Michal Arad, Timothy Ortlip, Benjamin A Portney, W Alex Meltzer, Silviu Diaconu, Lorna E Silipino, Ying Wang, David M Kaetzel, Rodney J Taylor and 1 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Stem cell research & therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Raju KhatriDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Michal AradDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Timothy OrtlipDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Benjamin A PortneyDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
W Alex MeltzerDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Silviu DiaconuDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Lorna E SilipinoDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Maryland School of Medicine, 108 N. Greene Street, Baltimore, MD, 21201, USA.
Ying WangDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
David M KaetzelDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Rodney J TaylorMarlene and Stewart Greenbaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
Michal ZalzmanDepartment of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. MZalzman@som.umaryland.edu.ORCID 0000-0002-4689-2951
University of Maryland, Baltimore · US

Funding

Suppression of Melanoma Initiation and Progression by NM23-H1R01CA159871 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI KAETZEL, DAVID M · 2012 to 2016
$2.2M
Enhancing the potency of aged adult stem cells for tissue reconstructionR01AR070819 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ZALZMAN, MICHAL · 2017 to 2021
$1.7M
A Novel Cell Therapy Approach to Augment Regeneration in Neurodegenerative DiseaseR21NS095088 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI ZALZMAN, MICHAL · 2017 to 2018
$425k
NCI NIH HHS R01 CA159871NIAMS NIH HHS R01 AR070819NINDS NIH HHS R21 NS095088
6 · The paper itself

Abstract

backgroundHuman adult stem cells hold the potential for the cure of numerous conditions and degenerative diseases. They possess major advantages over pluripotent stem cells as they can be derived from donors at any age, and therefore pose no ethical concerns or risk of teratoma tumor formation in vivo. Furthermore, they have a natural ability to differentiate and secrete factors that promote tissue healing without genetic manipulation. However, at present, clinical applications of adult stem cells are limited by a shortage of a reliable, standardized, and easily accessible tissue source which does not rely on specimens discarded from unrelated surgical procedures.

methodHuman tonsil-derived mesenchymal progenitor cells (MPCs) were isolated from a small sample of tonsillar tissue (average 0.88 cm

resultsWe have generated tonsillar biopsy-derived MPC (T-MPC) lines from multiple donors across a spectrum of age, sex, and race, and successfully expanded them in culture. We characterized them by cell surface markers, as well as in vitro expansion and differentiation potential. Our procedure provides a robust yield of tonsillar biopsy-derived T-MPCs.

conclusionsMillions of MPCs can be harvested from a sample smaller than 1 g, which can be collected from a fully awake donor in an outpatient setting without the need for general anesthesia or hospitalization. Our study identifies tonsillar biopsy as an abundant source of adult MPCs for regenerative medicine.

Indexed as

BiopsyCell SeparationFemaleHumansMaleMultipotent Stem CellsPalatine TonsilCell therapyMesenchymal progenitor cellsMultipotencyRegenerative medicineTonsil

Identifiers

PMID28750664
PMCPMC5531028
OpenAlexW2741007543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.